Profile data is unavailable for this security.
About the company
Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
- Revenue in EUR (TTM)5.73m
- Net income in EUR-20.55m
- Incorporated2006
- Employees100.00
- LocationAdocia SA115 avenue LacassagneLYON 69003FranceFRA
- Phone+33 472610610
- Fax+33 472363967
- Websitehttps://www.adocia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Maat Pharma SA | 2.31m | -14.73m | 102.22m | 47.00 | -- | 3.26 | -- | 44.18 | -1.39 | -1.39 | 0.2201 | 2.70 | 0.048 | 7.87 | 3.00 | 53,813.95 | -30.58 | -- | -38.13 | -- | 76.19 | -- | -636.60 | -- | 4.14 | -60.84 | 0.2931 | -- | 47.12 | -- | -52.05 | -- | -- | -- |
Ose Immunotherapeutics SA | 2.23m | -23.00m | 105.79m | 62.00 | -- | 4.57 | -- | 47.50 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
Transgene SA | 7.63m | -22.33m | 114.97m | 164.00 | -- | -- | -- | 15.06 | -0.22 | -0.22 | 0.0759 | -- | -- | -- | -- | -- | -- | -24.81 | -- | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | -- | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
Eurofins-Cerep SA | 46.17m | 9.21m | 116.01m | 233.00 | 12.59 | 1.93 | 10.36 | 2.51 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
Adocia SA | 5.73m | -20.55m | 125.25m | 100.00 | -- | -- | -- | 21.88 | -2.36 | -2.36 | 0.6532 | -1.90 | 0.1823 | -- | 16.79 | 55,048.08 | -65.43 | -25.65 | -341.43 | -37.22 | -- | -- | -358.85 | -101.11 | 0.5924 | -2.78 | 2.81 | -- | 692.73 | -10.08 | 69.67 | -- | -40.08 | -- |
DBV Technologies SA | 4.87m | -93.97m | 128.82m | 88.00 | -- | 0.8428 | -- | 26.46 | -0.9973 | -0.9973 | 0.0517 | 1.58 | 0.0209 | -- | 0.3738 | 70,562.52 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
AB Science SA | 777.00k | -16.89m | 129.21m | 89.00 | -- | -- | -- | 166.29 | -0.3561 | -0.3561 | 0.0164 | -0.3879 | 0.0284 | 0.394 | 2.50 | 7,471.15 | -61.64 | -70.81 | -237.22 | -316.63 | 88.16 | 91.37 | -2,173.10 | -1,225.49 | 1.41 | -- | 135.44 | -- | -40.39 | -11.24 | 5.86 | -- | 5.07 | -- |
Eurobio Scientific SA | 128.01m | 7.91m | 165.01m | 304.00 | 21.32 | 1.04 | 6.77 | 1.29 | 0.7552 | 0.7552 | 11.91 | 15.45 | 0.4856 | 3.75 | 4.48 | 948,222.30 | 3.00 | 21.70 | 3.53 | 28.79 | 45.28 | 50.59 | 6.18 | 25.06 | 2.70 | 4.11 | 0.3799 | 0.00 | -17.38 | 29.03 | -58.81 | -- | -6.24 | -- |
Genfit SA | 29.75m | -34.17m | 166.45m | 154.00 | -- | 2.23 | -- | 5.59 | -0.6877 | -0.6877 | 0.5988 | 1.50 | 0.1381 | 535.25 | 16.86 | 201,027.00 | -15.86 | -15.88 | -19.53 | -19.02 | 92.80 | 94.23 | -114.87 | -120.19 | 2.95 | -9.32 | 0.5030 | -- | -68.96 | 31.11 | -135.27 | -- | -- | -- |
Aelis Farma SA | 5.55m | -5.57m | 171.69m | 22.00 | -- | 9.98 | -- | 30.92 | -0.4123 | -0.4123 | 0.4187 | 1.30 | 0.1405 | -- | 1.36 | 252,409.10 | -14.09 | -30.28 | -22.24 | -49.56 | -- | -- | -100.29 | -168.22 | 2.41 | -- | 0.1337 | -- | -58.03 | -- | -2,589.20 | -- | -- | -- |
Inventiva SA | 14.01m | -80.08m | 173.02m | 117.00 | -- | -- | -- | 12.35 | -1.90 | -1.90 | 0.3357 | -0.182 | 0.1564 | -- | 12.60 | 124,008.90 | -89.37 | -40.86 | -136.45 | -49.44 | -- | -- | -571.45 | -747.46 | 1.37 | -25.03 | 1.28 | -- | 190.39 | 20.48 | -9.35 | -- | 5.56 | -- |
Innate Pharma SA | 51.90m | -7.57m | 176.68m | 191.00 | -- | 3.39 | -- | 3.40 | -0.0843 | -0.0843 | 0.617 | 0.6437 | 0.2648 | -- | 1.77 | -- | -3.86 | -8.83 | -4.87 | -12.11 | 65.19 | -- | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
Cellectis SA | 22.63m | -54.96m | 178.52m | -- | -- | 1.96 | -- | 7.89 | -1.05 | -1.54 | 0.4391 | 1.27 | 0.0998 | -- | 40.86 | -- | -27.15 | -21.38 | -34.66 | -26.37 | -- | -61.60 | -272.10 | -268.89 | -- | -4.96 | 0.5559 | -- | -33.35 | -5.27 | -5.77 | -- | -14.21 | -- |
Holder | Shares | % Held |
---|---|---|
NOVACAP Asset Management SAas of 31 Mar 2020 | 42.48k | 0.30% |
Uzes Gestion SAas of 23 Feb 2024 | 30.00k | 0.21% |
CGM � Azimut Monaco SAas of 31 Jan 2024 | 11.00k | 0.08% |
Gestys SAas of 26 Jan 2024 | 1.10k | 0.01% |
Iris Finance SAas of 31 Dec 2018 | 0.00 | 0.00% |